Literature DB >> 3427965

A comparison of the potencies and activities of progestogens used in contraceptives.

A Phillips1, D W Hahn, S Klimek, J L McGuire.   

Abstract

The potencies and activities of six progestational agents, norethindrone, levonorgestrel, desogestrel, medroxyprogesterone acetate (MPA), progesterone (P) and norgestimate have been evaluated using standard laboratory bioassays. The endocrine activities measured are those most closely related to the clinically important actions of contraceptives. Relative potencies varied with parameter measured, route of administration and species showing clearly that each progestogen is a distinct pharmacological entity. The order of potency using oral administration for either ovulation inhibition or endometrial stimulation in rabbits was desogestrel greater than levonorgestrel greater than MPA greater than norgestimate greater than norethindrone. Levonorgestrel was more androgenic than desogestrel, and P, norethindrone, norgestimate and MPA were essentially devoid of androgen activity. This profile demonstrates clear differences in the potencies and activities of these progestogens and in their selectivity for target organs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3427965     DOI: 10.1016/0010-7824(87)90013-8

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

1.  Trends in the content and use of oral contraceptives in the United States, 1964-88.

Authors:  B B Gerstman; T P Gross; D L Kennedy; R C Bennett; D K Tomita; B V Stadel
Journal:  Am J Public Health       Date:  1991-01       Impact factor: 9.308

Review 2.  Ovarian manipulation in ART: going beyond physiological standards to provide best clinical outcomes.

Authors:  Israel Ortega; Juan A García-Velasco; Antonio Pellicer
Journal:  J Assist Reprod Genet       Date:  2018-07-28       Impact factor: 3.412

3.  Transactivation of progestin- and estrogen-responsive promoters by 19-nor progestins in African Green Monkey Kidney CV1 cells.

Authors:  A M Pasapera; R Gutiérrez-Sagal; R García-Becerra; A Ulloa-Aguirre; J F Savouret
Journal:  Endocrine       Date:  2001-12       Impact factor: 3.633

Review 4.  Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women.

Authors:  M P Curran; A J Wagstaff
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Oral contraceptive use and breast cancer: a prospective study of young women.

Authors:  David J Hunter; Graham A Colditz; Susan E Hankinson; Susan Malspeis; Donna Spiegelman; Wendy Chen; Meir J Stampfer; Walter C Willett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-27       Impact factor: 4.254

Review 6.  Comparative pharmacology of newer progestogens.

Authors:  H Kuhl
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

7.  Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial.

Authors:  Erik E Hauzman; Azucena Zapata; Alfonso Bermejo; Carlos Iglesias; Antonio Pellicer; Juan A Garcia-Velasco
Journal:  Reprod Biol Endocrinol       Date:  2013-09-28       Impact factor: 5.211

8.  Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? A pilot study.

Authors:  David H Barad; Ann Kim; Hala Kubba; Andrea Weghofer; Norbert Gleicher
Journal:  Reprod Biol Endocrinol       Date:  2013-04-04       Impact factor: 5.211

9.  Hormonal content and potency of oral contraceptives and breast cancer risk among young women.

Authors:  M D Althuis; D R Brogan; R J Coates; J R Daling; M D Gammon; K E Malone; J B Schoenberg; L A Brinton
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.